×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ALLO – allogene therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ALLO
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/10
08:30 am
allo
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Medium
Report
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
11/7
06:11 pm
allo
Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T [Seeking Alpha]
Low
Report
Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T [Seeking Alpha]
11/6
04:05 pm
allo
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
High
Report
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
11/3
09:04 am
allo
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
Medium
Report
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
10/30
08:30 am
allo
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
Low
Report
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
10/10
08:06 am
allo
Allogene Therapeutics (NASDAQ:ALLO) had its "underweight" rating reaffirmed by analysts at JPMorgan Chase & Co..
High
Report
Allogene Therapeutics (NASDAQ:ALLO) had its "underweight" rating reaffirmed by analysts at JPMorgan Chase & Co..
Date
Time
Symbol
Company Name
Action
%Chg
11/6/2025
04:05 pm
allo
allogene therapeutics, inc.
BEAT
Report
12.4%
allogene therapeutics, inc.
8/13/2025
04:05 pm
allo
allogene therapeutics, inc.
BEAT
Report
0.9%
allogene therapeutics, inc.
5/13/2025
04:05 pm
allo
allogene therapeutics, inc.
IN-LINE
Report
-16.4%
allogene therapeutics, inc.
5/13/2025
04:05 pm
allo
allogene therapeutics, inc.
IN-LINE
Report
-16.4%
allogene therapeutics, inc.
Date
Time
Symbol
Headline
Impact
11/19
04:09 pm
allo
Form 4 Allogene Therapeutics, For: Nov 17 Filed by: Beneski Benjamin Machinas
Low
Report
Form 4 Allogene Therapeutics, For: Nov 17 Filed by: Beneski Benjamin Machinas
11/17
07:14 pm
allo
Form 144 Allogene Therapeutics, Filed by: Beneski Benjamin Machinas
Medium
Report
Form 144 Allogene Therapeutics, Filed by: Beneski Benjamin Machinas
11/13
07:10 pm
allo
Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Belldegrun Arie
Medium
Report
Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Belldegrun Arie
11/13
07:06 pm
allo
Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Capital World Investors
Medium
Report
Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Capital World Investors
11/12
04:37 pm
allo
Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Chang David D
Low
Report
Form SCHEDULE 13G/A Allogene Therapeutics, Filed by: Chang David D
11/6
04:31 pm
allo
Form 10-Q Allogene Therapeutics, For: Sep 30
High
Report
Form 10-Q Allogene Therapeutics, For: Sep 30
11/6
04:29 pm
allo
Form 8-K Allogene Therapeutics, For: Nov 06
High
Report
Form 8-K Allogene Therapeutics, For: Nov 06
10/23
06:21 pm
allo
Form 4 Allogene Therapeutics, For: Oct 21 Filed by: Parker Geoffrey M.
Low
Report
Form 4 Allogene Therapeutics, For: Oct 21 Filed by: Parker Geoffrey M.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/6
Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule
6.8%
3/18 Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Chang David D 6.8%
3/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.7%
4/23 Form DEF 14A Allogene Therapeutics, For: Dec 31 5.9%
4/28 Form 4 Allogene Therapeutics, For: Apr 24 Filed by: Chang David D 5.9%
4/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.5%
8/7 Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.0%
3/24 MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies 4.9%
3/13 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $35.00 price target on the stock. 4.7%
2/24 Form 4 Allogene Therapeutics, For: Feb 20 Filed by: SCHMIDT ERIC THOMAS 4.4%
3/18 Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Chang David D 6.8%
3/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.7%
4/23 Form DEF 14A Allogene Therapeutics, For: Dec 31 5.9%
4/28 Form 4 Allogene Therapeutics, For: Apr 24 Filed by: Chang David D 5.9%
4/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.5%
8/7 Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.0%
3/24 MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies 4.9%
3/13 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $35.00 price target on the stock. 4.7%
2/24 Form 4 Allogene Therapeutics, For: Feb 20 Filed by: SCHMIDT ERIC THOMAS 4.4%
TOP News Decliners
3/12
Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating.
-15.8%
11/6 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -6.4%
8/11 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -5.4%
8/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.2%
3/20 Senator Richard Burr Sold a Fortune in Stocks While Playing Down Coronavirus Threat [The New York Times] -5.1%
11/12 Allogene Moves Forward With CAR-T Therapy Pipeline [Seeking Alpha] -5.1%
4/1 Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences -4.9%
9/25 Form 4 Allogene Therapeutics, For: Sep 23 Filed by: Kazam Joshua A -4.8%
5/22 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at Stifel Nicolaus. They set a "hold" rating on the stock. -4.8%
11/5 Q3/2019 9/30/2019 EPS -0.500 ZacksConsensus -0.540 ActVsEst 0.040 - Beat -4.4%
11/6 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -6.4%
8/11 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -5.4%
8/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.2%
3/20 Senator Richard Burr Sold a Fortune in Stocks While Playing Down Coronavirus Threat [The New York Times] -5.1%
11/12 Allogene Moves Forward With CAR-T Therapy Pipeline [Seeking Alpha] -5.1%
4/1 Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences -4.9%
9/25 Form 4 Allogene Therapeutics, For: Sep 23 Filed by: Kazam Joshua A -4.8%
5/22 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at Stifel Nicolaus. They set a "hold" rating on the stock. -4.8%
11/5 Q3/2019 9/30/2019 EPS -0.500 ZacksConsensus -0.540 ActVsEst 0.040 - Beat -4.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: